Compare · CARL vs DXCM
CARL vs DXCM
Side-by-side comparison of Carlsmed Inc. (CARL) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CARL and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 101.3x CARL ($277.3M).
- Over the past year, CARL is down 29.4% and DXCM is down 16.2% - DXCM leads by 13.2 points.
- DXCM has been more active in the news (30 items in the past 4 weeks vs 1 for CARL).
- DXCM has more recent analyst coverage (25 ratings vs 5 for CARL).
- Company
- Carlsmed Inc.
- DexCom Inc.
- Price
- $10.21-0.29%
- $72.74-0.92%
- Market cap
- $277.3M
- $28.08B
- 1M return
- +11.83%
- +21.17%
- 1Y return
- -29.37%
- -16.20%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2005
- News (4w)
- 1
- 30
- Recent ratings
- 5
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CARL
- Carlsmed Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 10-Q filed by Carlsmed Inc.
- Carlsmed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Carlsmed® Reports First Quarter 2026 Financial Results
- Carlsmed, Inc. To Participate in Upcoming Investor Conferences
- SEC Form DEFA14A filed by Carlsmed Inc.
- SEC Form DEF 14A filed by Carlsmed Inc.
- Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
- Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
- CEO, President Cordonnier Michael exercised 391,686 shares at a strike of $0.68 and sold $2,629,889 worth of shares (197,855 units at $13.29), increasing direct ownership by 14% to 1,550,477 units (SEC Form 4)
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)